Evidence map›Paper›PMID 28236576›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017

Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment.

Xiaohui Zhang, Austin Bohner, Sai Bhuvanagiri, Hironori Uehara, Arun Kumar Upadhyay, Lyska L Emerson, Sailaja Bondalapati, Santosh Kumar Muddana, Daniel Fang, Miaoling Li and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. New Therapies of Neovascular AMD-Beyond Anti-VEGFs.Vision (Basel, Switzerland) · 2018
    Review
  8. Nanoparticle Technology: Having Impact, but Needing Further Optimization.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Xiaohui ZhangMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Austin BohnerMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Sai BhuvanagiriMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Hironori UeharaMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Arun Kumar UpadhyayUniversity of Colorado School of Pharmacy, Mail Stop C238, 12850 E. Montview Blvd. V20-4129, Aurora, CO 80045, USA.
Lyska L EmersonDepartment of Pathology, University of Utah and Associated Regional and University Pathologists (ARUP) Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108, USA.
Sailaja BondalapatiMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Santosh Kumar MuddanaMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Daniel FangMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Miaoling LiMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.
Zoya SandhuMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Alya HussainMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Lara S CarrollMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Michelle TiemMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Bonnie ArcherMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Uday KompellaUniversity of Colorado School of Pharmacy, Mail Stop C238, 12850 E. Montview Blvd. V20-4129, Aurora, CO 80045, USA.
Rajkumar PatilSingapore Eye Research Institute, Singapore 169856, Singapore.
Balamurali K AmbatiMoran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA. Electronic address: bala.ambati@utah.edu.
University of Utah · USUniversity of Colorado Denver · USSingapore Eye Research Institute · SGSun Yat-sen University · CNUniversity Pathologists · US

Funding

Intraceptor Interference of VEGF PathwaysR01EY017182 · NEI · UNIVERSITY OF UTAH · PI AMBATI, BALAMURALI K · 2007 to 2017
$3.6M
MSRP in Metabolism, Diabetes, Digestive and Kidney DiseasesT35DK103596 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN, ROUND, JUNE LOUISE · 2015 to 2025
$758k
NEI NIH HHS R01 EY017182NIDDK NIH HHS T35 DK103596
6 · The paper itself

Abstract

Neovascular age-related macular degeneration (AMD) is treated with anti-VEGF intravitreal injections, which can cause geographic atrophy, infection, and retinal fibrosis. To minimize these toxicities, we developed a nanoparticle delivery system for recombinant Flt23k intraceptor plasmid (RGD.Flt23k.NP) to suppress VEGF intracellularly within choroidal neovascular (CNV) lesions in a laser-induced CNV mouse model through intravenous administration. In the current study, we examined the efficacy and safety of RGD.Flt23k.NP in mice. The effect of various doses was determined using fluorescein angiography and optical coherence tomography to evaluate CNV leakage and volume. Efficacy was determined by the rate of inhibition of CNV volume at 2 weeks post-treatment. RGD.Flt23k.NP had peak efficacy at a dose range of 30-60 μg pFlt23k/mouse. Using the lower dose (30 μg pFlt23k/mouse), RGD.Flt23k.NP safety was determined both in single-dose groups and in repeat-dose (three times) groups by measuring body weight, organ weight, hemoglobin levels, complement C3 levels, and histological changes in vital organs. Neither toxicity nor inflammation from RGD.Flt23k.NP was detected. No side effect was detected on visual function. Thus, systemic RGD.Flt23k.NP may be an alternative to standard intravitreal anti-VEGF therapy for the treatment of neovascular AMD.

Indexed as

Drug CarriersAngiogenesis InhibitorsAnimalsChoroidChoroidal NeovascularizationComplement C3Disease Models, AnimalDose-Response Relationship, DrugDrug Evaluation, PreclinicalFemaleGene Expression RegulationHemoglobinsHumansInjections, IntravenousIntravitreal InjectionsLasersAngiogenesis InhibitorsComplement C3Drug CarriersHemoglobinsVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseage-related macular degenerationRGD.Flt23k.NP efficacyRGD.Flt23k.NP safety

Identifiers

PMID28236576
PMCPMC5498805
OpenAlexW2581169165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.